Plenary conference: Auto, alo and islet xenotransplantation
DOI:
https://doi.org/10.47196/diab.v54i3Sup.309Keywords:
islet transplantation, diabetesAbstract
Plenary conference: Auto, alo and islet xenotransplantation
Islet transplantation is a cell therapeutic approach finalized to improve glycemic control in patients that have lost beta cells to autoimmune destruction (as in type 1 diabetes) or due to surgical excision of the pancreas (typically for severe, untreatable chronic pancreatitis).
Autologous islet transplantation entails the isolation of pancreatic islets from one patient undergoing total pancreatectomy and intraportal infusion of the islets to the same patient in order to maintain endogenous production of insulin in the absence of immune rejection. This is a clinically viable procedure that successfully allows at least 60% of islet autotransplantation recipients to control glycemias often enjoying years of insulin independence.
References
-1- JACS 2012;214:409-26
-2- JCEM 2015;100:1765-70-395
-3- Diabetes Care, 35:436-45, 2012
-4- Diabetes Care. 2016 Jul;39(7):1230-40
-5- Science. 2003 January 17; 299(5605): 411-414.
-6- Xenotransplantation. 2020; 27(3): e12621.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
